Maia Biotechnology

Maia Biotechnology ROE

The Return on Equity (ROE) of Maia Biotechnology (MAIA) as of Nov 10, 2026 is -942.65 %. In the previous year, Return on Equity (ROE) was -639.81 % — a change of 47.33% (lower).

ROE

-942.65 %

YoY

47.33%

Last updated:

In 2025, Maia Biotechnology's return on equity (ROE) was -942.65 %, a 47.33% increase from the -639.81 % ROE in the previous year.

The Maia Biotechnology ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
3,755.94 USD
Jan 1, 2020
198.94 USD
Jan 1, 2021
-136.19 USD
Jan 1, 2022
-185.35 USD
Jan 1, 2023
-4,140.83 USD
Jan 1, 2024
-639.81 USD
Jan 1, 2025
-942.65 USD
The Maia Biotechnology ROE history
YEARROEYoY
-942.65 %+47.33%
-639.81 %-84.55%
-4,140.83 %+2,134.05%
-185.35 %+36.10%
-136.19 %-168.46%
198.94 %-94.70%
3,755.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Maia Biotechnology Stock analysis

What does Maia Biotechnology do? MAIA Biotechnology, Inc. generates revenue through the development and commercialization of oncology drug candidates, focusing on targeted immuno-oncology therapies for difficult-to-treat cancers. The company's pipeline includes THIO (6-thio-dG, 6-thio-2’-deoxyguanosine), a telomere-targeting agent in Phase II clinical development for Non-Small Cell Lung Cancer, and Libtayo for advanced non-small-cell lung cancer treatment. MAIA is advancing a second-generation program with five compounds designed to improve specificity towards cancer cells and increase anticancer activity. The firm targets pharmaceutical companies and healthcare providers seeking innovative cancer treatments. The company's primary products are THIO and Libtayo, with THIO being a potentially first-in-class small molecule. MAIA is developing these therapies to improve and extend the lives of cancer patients, focusing on non-small-cell lung cancer and other difficult-to-treat cancers. The firm's second-generation pipeline aims to discover new compounds with enhanced properties compared to existing therapies. MAIA's clinical-stage approach allows it to partner with pharmaceutical entities for development and commercialization. MAIA Biotechnology's revenue model relies on the progression of its clinical-stage therapies through development phases, with potential partnerships and licensing agreements for commercialization. The company's focus on telomere-targeting agents like THIO positions it in the oncology drug development market. MAIA's pipeline includes Phase II studies for THIO in Non-Small Cell Lung Cancer, indicating near-term potential for partnerships or sales. The firm targets healthcare providers and pharmaceutical companies as key segments for its therapies. Maia Biotechnology is one of the most popular companies on Eulerpool.

ROE Details

Decoding Maia Biotechnology's Return on Equity (ROE)

Maia Biotechnology's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Maia Biotechnology's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Maia Biotechnology's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Maia Biotechnology’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Maia Biotechnology stock

Return on Equity (ROE) of Maia Biotechnology is -942.65 % in 2025.

Return on Equity (ROE) of Maia Biotechnology changed from -639.81 % to -942.65 %, representing a 47.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Maia Biotechnology since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Maia Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Maia Biotechnology

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Maia Biotechnology